Wire · opportunities
Unmet Clinical Needs in Biomarker-Guided Immune Checkpoint Inhibitor Treatment
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 7 October 2026 · Fusion42 review
Current FDA-approved biomarkers for immune checkpoint inhibitor therapy have limited predictive accuracy, leaving clinical uncertainty for many cancer patient populations. Key gaps include lack of tools to match patients with the most effective ICI mechanism, guidance on post-progression or biomarker-negative patients, and management of special cases such as immune dysregulation or liver metastases.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
Your biotech startup must prepare for a wave of new biomarker tools that promise to clarify ICI patient selection, as current FDA-approved markers leave over 80% of eligible patients uncertain responders. This gap creates an opening to develop diagnostics that reshape treatment decisions and capture market share.
◆ Coverage
1 source · 6 Oct 2026
◆ Related on Wire
◆ Topics